SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin launches Olmesartan Medoxomil tablets in US markets

04 Sep 2017 Evaluate

Lupin has launched Olmesartan Medoxomil tablets 5 mg, 20 mg and 40 mg in the US markets having received an approval from the United States Food and Drug Administration (USFDA) earlier.

The company’s Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Benicar tablets. It is indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents, to lower blood pressure. Benicar tablets had US sales of $681 million as per IMS MAT July 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2241.10 -136.80 (-5.75%)
11-May-2026 15:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1871.75
Dr. Reddys Lab 1279.65
Cipla 1303.45
Zydus Lifesciences 960.00
Lupin 2241.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×